Rabeau A, Rouquette I, Vantelon J-M, Taranchon-Clermont E, Mazières J
Service de pneumologie, hôpital Larrey, université Paul-Sabatier, CHU de Toulouse, 31400 Toulouse, France.
Service de pathologie, IUCT-Oncopole, CHU de Toulouse, 31100 Toulouse, France.
Rev Mal Respir. 2017 Jan;34(1):57-60. doi: 10.1016/j.rmr.2016.05.007. Epub 2016 Oct 13.
Targeted therapy in lung cancer changes the prognostic and treatment of patients. MET is an oncogene including exon 14 mutations and gene amplification associated with worse prognosis. We here report the case of a 47-year-old former smoker, woman, with a stage IV lung adenocarcinoma with multiple chemotherapy failure. A MET amplification was identified and the patient consequently received crizotinib. A major response was observed after eight weeks of treatment. MET amplification screening appears to be interesting with some oncogenic-addicted tumor response rate. Those patients should be enrolled in clinical trials dedicated to tumor with MET alteration.
肺癌的靶向治疗改变了患者的预后和治疗方式。MET是一种致癌基因，包括与较差预后相关的外显子14突变和基因扩增。我们在此报告一例47岁的既往吸烟者女性，患有IV期肺腺癌且多次化疗失败。检测到MET扩增，该患者因此接受了克唑替尼治疗。治疗八周后观察到显著反应。MET扩增筛查对于某些致癌成瘾性肿瘤反应率似乎很有意义。这些患者应纳入专门针对MET改变肿瘤的临床试验。
